These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 3223647)
1. [Registration of peranesthetic cases of malignant hyperthermia in France. An update]. Jacquot C; Stieglitz P; Kozak-Reiss G; Krivosic-Horber R; Laxenaire MC; Lienhart A; Nivoche Y Ann Fr Anesth Reanim; 1988; 7(6):524-34. PubMed ID: 3223647 [TBL] [Abstract][Full Text] [Related]
2. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests]. Mortier W; Breucking E Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201 [TBL] [Abstract][Full Text] [Related]
3. Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy. Carr AS; Lerman J; Cunliffe M; McLeod ME; Britt BA Can J Anaesth; 1995 Apr; 42(4):281-6. PubMed ID: 7788824 [TBL] [Abstract][Full Text] [Related]
4. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Riazi S; Larach MG; Hu C; Wijeysundera D; Massey C; Kraeva N Anesth Analg; 2014 Feb; 118(2):381-387. PubMed ID: 23842196 [TBL] [Abstract][Full Text] [Related]
5. Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis. O'Flynn RP; Shutack JG; Rosenberg H; Fletcher JE Anesthesiology; 1994 Jun; 80(6):1228-33. PubMed ID: 8010468 [TBL] [Abstract][Full Text] [Related]
6. Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil. Sudo RT; Cunha LB; Carmo PL; Matos AR; Trachez MM; Cardoso LA; Aguiar MI; Abreu AV; Zapata-Sudo G Braz J Med Biol Res; 2010 Jun; 43(6):549-56. PubMed ID: 20464345 [TBL] [Abstract][Full Text] [Related]
7. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391 [TBL] [Abstract][Full Text] [Related]
8. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle. Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688 [TBL] [Abstract][Full Text] [Related]
9. A Single-Center Retrospective Review of Patients with Suspected Malignant Hyperthermia Susceptibility. Edwards C; Dooley FC; Gonzalez S; Austin TM; Gravenstein N Cureus; 2023 Sep; 15(9):e44661. PubMed ID: 37799222 [TBL] [Abstract][Full Text] [Related]
10. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Larach MG; Brandom BW; Allen GC; Gronert GA; Lehman EB Anesth Analg; 2014 Dec; 119(6):1359-66. PubMed ID: 25268394 [TBL] [Abstract][Full Text] [Related]
11. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia. Ording H; Bendixen D Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623 [TBL] [Abstract][Full Text] [Related]
12. Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test. Bendixen D; Skovgaard LT; Ording H Acta Anaesthesiol Scand; 1997 Apr; 41(4):480-4. PubMed ID: 9150775 [TBL] [Abstract][Full Text] [Related]
13. Malignant hyperthermia in maxillofacial surgery: Literature review supported by case presentation. Aires CCG; de Souza RRL; Amorim JA; Santos FG; Diniz DA; Carneiro SCAS; Vasconcellos RJH Spec Care Dentist; 2023 Jan; 43(1):99-108. PubMed ID: 35667046 [TBL] [Abstract][Full Text] [Related]
14. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia. Hopkins PM; Ellis FR; Halsall PJ; Stewart AD Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318 [TBL] [Abstract][Full Text] [Related]
15. [Incidence of disposition for malignant hyperthermia in patients with neuromuscular diseases]. Wappler F; Scholz J; von Richthofen V; Fiege M; Köchling A; Matschke J; Winkler G; Schulte am Esch J Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Jun; 33(6):373-80. PubMed ID: 9689395 [TBL] [Abstract][Full Text] [Related]
16. [Clinical features of malignant hyperthermia crisis]. Cornet C; Moeller R; Laxenaire MC Ann Fr Anesth Reanim; 1989; 8(5):435-43. PubMed ID: 2516711 [TBL] [Abstract][Full Text] [Related]
17. Muscular body build and male sex are independently associated with malignant hyperthermia susceptibility. Butala B; Brandom B Can J Anaesth; 2017 Apr; 64(4):396-401. PubMed ID: 28063098 [TBL] [Abstract][Full Text] [Related]
18. Succinylcholine Use and Dantrolene Availability for Malignant Hyperthermia Treatment: Database Analyses and Systematic Review. Larach MG; Klumpner TT; Brandom BW; Vaughn MT; Belani KG; Herlich A; Kim TW; Limoncelli J; Riazi S; Sivak EL; Capacchione J; Mashman D; Kheterpal S; Kooij F; Wilczak J; Soto R; Berris J; Price Z; Lins S; Coles P; Harris JM; Cummings KC; Berman MF; Nanamori M; Adelman BT; Wedeven C; LaGorio J; McCormick PJ; Tom S; Aziz MF; Coffman T; Ellis TA; Molina S; Peterson W; Mackey SC; van Klei WA; Ginde AA; Biggs DA; Neuman MD; Craft RM; Pace NL; Paganelli WC; Durieux ME; Nair BJ; Wanderer JP; Miller SA; Helsten DL; Turnbull ZA; Schonberger RB; Anesthesiology; 2019 Jan; 130(1):41-54. PubMed ID: 30550426 [TBL] [Abstract][Full Text] [Related]
19. Dantrolene dose response in malignant hyperthermia-susceptible (MHS) swine: method to obtain prophylaxis and therapeusis. Flewellen EH; Nelson TE Anesthesiology; 1980 Apr; 52(4):303-8. PubMed ID: 7362049 [TBL] [Abstract][Full Text] [Related]
20. [Anesthetic complications. The incidence of severe anesthetic complications in patients and families with progressive muscular dystrophy of the Duchenne and Becker types]. Breucking E; Reimnitz P; Schara U; Mortier W Anaesthesist; 2000 Mar; 49(3):187-95. PubMed ID: 10788987 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]